Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors
نویسندگان
چکیده
منابع مشابه
Safety of sodium-glucose co-transporter 2 inhibitors during Ramadan fasting: Evidence, perceptions and guidelines
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new glucose-lowering therapy for T2DM with documented benefits on blood glucose, hypertension, weight reduction and long term cardiovascular benefit. They have an inherent osmotic diuretic effect and lead to some volume loss and possible dehydration. There is some concern about the safety of using SGLT2 inhibitors in Muslim type 2 diabete...
متن کاملsafety of sodium-glucose co-transporter 2 inhibitors during ramadan fasting: evidence, perceptions and guidelines
sodium-glucose co-transporter 2 (sglt2) inhibitors are a new glucose-lowering therapy for t2dm with documented benefits on blood glucose, hypertension, weight reduction and long term cardiovascular benefit. they have an inherent osmotic diuretic effect and lead to some volume loss and possible dehydration. there is some concern about the safety of using sglt2 inhibitors in muslim type 2 diabete...
متن کاملSodium-Glucose Cotransporter 2 Inhibitors for Heart Failure
In this issue (P94), Kutoh reports type 2 diabetic patients who showed changes in cardiac function which is concomitant with changes in ketone bodies by using one of sodium glucose cotransporter 2 inhibitors (SGLT2i), tofogliflozin [1], proposing a possible mechanism for SGLT2i-mediated prevention of heart failure. EMPA-REG OUTCOME trial showed a striking relative risk reduction in hospitalizat...
متن کاملSodium glucose co-transporter 2 inhibitors in patients with resistant hypertension: a case study
Sodium glucose co-transporter 2 inhibitors lower blood pressure by osmotic diuresis and can be considered in diabetic patients with resistant hypertension.
متن کاملSodium Glucose Co-Transporter 2 (SGLT-2) Inhibitors: A Review Authors
Worldwide, the number of individuals with diabetes is projected to rise from 366 million in 2011 to 552 million by end of 2030. Despite therapeutic advances, the incidence and prevalence of diabetes continues to surge exacting a tremendous economic burden on countries. The major problem with diabetes is that just 50% of population is able to achieve target glycaemic control with available medic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The American Journal of Cardiology
سال: 2019
ISSN: 0002-9149
DOI: 10.1016/j.amjcard.2019.10.026